510(k) Modifications Guidance Shows FDA Focus On Least- Burdensome Principle, Routine Risk Tests
Executive Summary
A final 510(k) modifications guidance released from US FDA contains at least nine changes in emphasis from an August 2016 proposal. It enunciates the agency's plan to abide by "the least burdensome principle" in evaluating sponsors submissions for changes, and it recommends that any decision by a company not to submit a new 510(k) after a device alteration be routinely verified and validated.
You may also be interested in...
US FDA Updates Policy For Adding Cleared Assays To Additional Instruments
Under a draft guidance, IVD manufacturers wouldn’t need to submit a new 510(k) if they were clearing an assay for use with an instrument similar to those it was already cleared on.
Despite 510(k) Software Guidance, US FDA's Hands May Still Be Tied
While a recent final guidance when a 510(k) is needed for software changes is helpful, a key industry lobbyist says it doesn't do enough to address the bigger issue of allowing FDA more discretion to let software medical device-makers update their products quickly without burdensome agency oversight.
510(k) Modifications Guidance Docs Finalized At Long Last
After years of controversy, US FDA finally succeeded in updating its 20-year-old guideline on when a new 510(k) is needed for device modifications. Split out as its own document is a guideline targeting the issue specifically for software modifications.